The design of the software system for the interpretation and guidance of drug locus related to drug treatment_Journal of Biomedical Engineering

Authors：

DING Ruifeng ¹ , XU Xiulin ¹ , QING Tao ² ,  HU Xiufang ¹

1. School of Medical Instrument and Food Engineering, University of Shanghai for Science and Technology, Shanghai 200093, P.R.China;
2. School of Life Sciences, Fudan University, Shanghai 200438, P.R.China;

Corresponding author：

HU Xiufang, Email: huxiufang1965@163.com

Keywords：

pharmacogenomics; precise medication; container virtualization

DOI：

10.7507/1001-5515.201805001

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

Based on the pharmacogenomics theory, this study developed a software system for interpretation of drug gene loci and guidance on clinical safe medication with the purpose of providing clinical guidance on the safety and effectiveness of drug use through accurate and efficient detection and interpretation of drug gene loci. The system infrastructure was built on a service-oriented architecture (SOA) design and Docker container virtualization approach to achieve a rapid and automatic interpretation of genetic results and best available drugs. The front end was established on HTML5 and JavaScript to realize visualization of analysis results and user interaction. The system was tested and validated to show robust performance which is reliable in clinical use. It will show high impact on the development of pharmacogenomics and clinical practice of patients with personalized medicine.

Citation： DING Ruifeng, XU Xiulin, QING Tao, HU Xiufang. The design of the software system for the interpretation and guidance of drug locus related to drug treatment. Journal of Biomedical Engineering, 2019, 36(4): 657-663. doi: 10.7507/1001-5515.201805001 Copy

1.	Giacomini K M, Yee S W, Ratain M J, et al. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med, 2012, 4(153): ps18.
2.	Wang L, Mcleod H L, Weinshilboum R M. Genomics and drug response. New Engl J Med, 2011, 364(12): 1144-1153.
3.	Roederer M W, McLeod H L. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics, 2010, 11(5): 633-636.
4.	Weinshilboum R M, Wang Liewei. Pharmacogenetics and pharmacogenomics: development, science, and translation. Ann Rev Genom Hum Gen, 2006, 7(7): 223-245.
5.	van der Wouden C H, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther, 2017, 101(3): 341-358.
6.	王涛, 王丹, 董铎, 等. 美国药物警戒体系浅析及对我国的启示. 医药导报, 2017, 36(4): 361-365.
7.	张晓丹, 向倩, 胡琨, 等. 药物基因组学在新药临床研究中的应用现状. 中国临床药理学杂志, 2017, 33(23): 2508-2510.
8.	徐冠, 禹建春, 吴昌枝. 基层医院药品不良反应的综合分析与对策. 中医药管理杂志, 2018, 26(1): 79-80.
9.	耿春梅, 郭瑞臣. 药物基因组学在新药临床试验及个体化用药中的应用. 药学进展, 2015, 39(11): 803-809.
10.	Wishart D S, Feunang Y D, Guo A C, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research, 2018, 46(D1): 1074-1082.
11.	Barbarino J M, Whirl-Carrillo M, Altman R B, et al. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med, 2018, 10(4): e1417.
12.	Lester J, Neyarapally G A, Lipowski E, et al. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf, 2013, 22(3): 302-305.
13.	Ewing B, Hillier L D, Wendl M C, et al. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Research, 1998, 8(3): 175-185.
14.	Sztriha L K, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci, 2005, 229-230(3): 163-169.
15.	Moriyama B, Obeng A O, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther, 2017, 102(1): 45-51.
16.	Mega J L, Hochholzer W, Frelinger A L, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA, 2011, 306(20): 2221-2228.
17.	Shiotani A, Murao T, Fujita Y, et al. Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. PLoS One, 2013, 8(12): e84244.
18.	Sharma V, Kaul S, Al-Hazzani A, et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis, 2013, 35(1): 95-99.
19.	王玮霄, 禚艳丽. 比较阿司匹林与氯吡格雷对脑梗死患者的临床疗效与不良反应. 中国现代药物应用, 2018, 12(3): 3-5.

1. Giacomini K M, Yee S W, Ratain M J, et al. Pharmacogenomics and patient care: one size does not fit all. Sci Transl Med, 2012, 4(153): ps18.
2. Wang L, Mcleod H L, Weinshilboum R M. Genomics and drug response. New Engl J Med, 2011, 364(12): 1144-1153.
3. Roederer M W, McLeod H L. Applying the genome to national drug formulary policy in the developing world. Pharmacogenomics, 2010, 11(5): 633-636.
4. Weinshilboum R M, Wang Liewei. Pharmacogenetics and pharmacogenomics: development, science, and translation. Ann Rev Genom Hum Gen, 2006, 7(7): 223-245.
5. van der Wouden C H, Cambon-Thomsen A, Cecchin E, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharmacol Ther, 2017, 101(3): 341-358.
6. 王涛, 王丹, 董铎, 等. 美国药物警戒体系浅析及对我国的启示. 医药导报, 2017, 36(4): 361-365.
7. 张晓丹, 向倩, 胡琨, 等. 药物基因组学在新药临床研究中的应用现状. 中国临床药理学杂志, 2017, 33(23): 2508-2510.
8. 徐冠, 禹建春, 吴昌枝. 基层医院药品不良反应的综合分析与对策. 中医药管理杂志, 2018, 26(1): 79-80.
9. 耿春梅, 郭瑞臣. 药物基因组学在新药临床试验及个体化用药中的应用. 药学进展, 2015, 39(11): 803-809.
10. Wishart D S, Feunang Y D, Guo A C, et al. DrugBank 5.0: a major update to the DrugBank database for 2018. Nucleic Acids Research, 2018, 46(D1): 1074-1082.
11. Barbarino J M, Whirl-Carrillo M, Altman R B, et al. PharmGKB: A worldwide resource for pharmacogenomic information. Wiley Interdiscip Rev Syst Biol Med, 2018, 10(4): e1417.
12. Lester J, Neyarapally G A, Lipowski E, et al. Evaluation of FDA safety-related drug label changes in 2010. Pharmacoepidemiol Drug Saf, 2013, 22(3): 302-305.
13. Ewing B, Hillier L D, Wendl M C, et al. Base-calling of automated sequencer traces using phred. I. Accuracy assessment. Genome Research, 1998, 8(3): 175-185.
14. Sztriha L K, Sas K, Vecsei L. Aspirin resistance in stroke: 2004. J Neurol Sci, 2005, 229-230(3): 163-169.
15. Moriyama B, Obeng A O, Barbarino J, et al. Clinical pharmacogenetics implementation consortium (CPIC) guidelines for CYP2C19 and voriconazole therapy. Clin Pharmacol Ther, 2017, 102(1): 45-51.
16. Mega J L, Hochholzer W, Frelinger A L, et al. Dosing clopidogrel based on CYP2C19 genotype and the effect on platelet reactivity in patients with stable cardiovascular disease. JAMA, 2011, 306(20): 2221-2228.
17. Shiotani A, Murao T, Fujita Y, et al. Novel single nucleotide polymorphism markers for low dose aspirin-associated small bowel bleeding. PLoS One, 2013, 8(12): e84244.
18. Sharma V, Kaul S, Al-Hazzani A, et al. Association of COX-2 rs20417 with aspirin resistance. J Thromb Thrombolysis, 2013, 35(1): 95-99.
19. 王玮霄, 禚艳丽. 比较阿司匹林与氯吡格雷对脑梗死患者的临床疗效与不良反应. 中国现代药物应用, 2018, 12(3): 3-5.

Journal of Biomedical Engineering

The design of the software system for the interpretation and guidance of drug locus related to drug treatment

Abstract Full text Figures/Tables Video References Cited by

Previous Article

Next Article

Format

Content